Eton Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Illinois, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
21925 W Field Pkwy Ste 235, Deer Park, I...Phone Number
(847) 787-7361Website
www.etonpharma.comRevenue
$86.9 MillionStock Symbol
ETONIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Explore more
Eton Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eton Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Eton Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at Eton Pharmaceuticals
Check out if Eton Pharmaceuticals is spiking on competitors!
Click to see if Eton Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Eton Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Eton Pharmaceuticals recently announced quarterly report
Check if Eton Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Eton Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Eton Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Eton Pharmaceuticals
Compare insights from companies similar to Eton Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Eton Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Eton Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Eton Pharmaceuticals.
Eton Pharmaceuticals financials insights
Gather financial insights about Eton Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
Eton Pharmaceuticals Tech Stack
A closer look at the technologies used by Eton Pharmaceuticals
See more technologies
Most Recent Scoops
Earnings
Eton Pharmaceuticals has projected potential peak sales of $500 million or more by 2030, driven by its existing commercial infrastructure and internal pipeline.
Sales
Earnings
Eton Pharmaceuticals has reported projected revenues of north of $120 million for fiscal year 2026, with a targeted run rate exceeding $200 million annually by the end of 2027.
Earnings, Forecasting, Finance
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Earnings, Product Launch, Finance
Eton Pharmaceuticals News & Media
Eton Pharmaceuticals Q1 Earnings Call Highlights
Eton Pharmaceuticals (NASDAQ:ETON) raised its 2026 revenue outlook after reporting record first-quarter product sales and highlighting early progress from two recent product launches, DESMODA and HEMANGEOL. Chief Executive Officer Sean Brynjelsen said the company now expects full-year revenue to exEton Pharmaceuticals Reports First Quarter 2026 Financial Results
DEER PARK, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended March 31, 2026.Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
DEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that executive management will participate in three upcoming investor conferences as follows:Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
DEER PARK, Ill., May 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2026 financial results on Thursday, May 14, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eton Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperamm... Read More
